Merrimack Pharma (MACK) – Hot Corp. News
-
Merrimack Pharma (MACK) Confirms Ipsen's Onivyde Regimen Demonstrated Statistically Significant Improvement in OS in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
-
Merrimack Pharma (MACK) Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MACK Stock Lookup